Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord BiotechBOM:543960 +0.67%68 Days Payable is 108.36 as of Mar. 2026, which is 28% below its 10-year median of 150.89. GuruFocus rates BOM:543960 with a GF Score™ of 68/100 and a GF Value™ of ₹1,666.31 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 701 Biotechnology companies, Concord Biotech ranks better than 56.78% on this metric.
The historical rank and industry rank for Concord Biotech's Days Payable or its related term are showing as below:
BOM:543960'
s Days Payable Range Over the Past 10 Years
Min: 119.18 Med: 150.89 Max: 189.15
Current: 149.33
During the past 7 years, Concord Biotech's highest Days Payable was 189.15. The lowest was 119.18. And the median was 150.89.
BOM:543960's Days Payable is ranked better than 56.78% of 701
companies
in the Biotechnology industry
Industry Median: 113.36
vs BOM:543960: 149.33
Concord Biotech's Days Payable
increased
from Mar. 2025 (80.27) to Mar. 2026 (108.36).
It may suggest that Concord Biotechdelayed paying its suppliers.
Concord Biotech Days Payable Related Terms
Concord Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Concord Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543960 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Concord Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Concord Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Concord Biotech's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Biotech (BOM:543960) has a Days Payable of 108.36 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Concord Biotech and its competitors. This is 28% below median its historical median of 150.89. Over the past decade, Concord Biotech's Days Payable has ranged from 119.18 to 189.15. According to the industry distribution chart, Concord Biotech ranks #303 out of 701 companies in the Biotechnology industry, placing it in the top 43.2%.
Is Concord Biotech's Days Payable too high?
Concord Biotech's current Days Payable of 108.36 is 28% below median its 10-year median of 150.89. Over the past 10 years, this metric has ranged from a low of 119.18 to a high of 189.15. The Biotechnology industry median Days Payable is 113.36. Concord Biotech's value of 108.36 is 4.4% below this industry median. Based on the distribution chart, Concord Biotech ranks #303 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Concord Biotech has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #303 out of 701 companies for Days Payable. This puts Concord Biotech in the upper half of its industry. The industry median Days Payable is 113.36. Concord Biotech's value of 108.36 is 4.4% below this benchmark. Historically, Concord Biotech's own Days Payable has ranged from 119.18 to 189.15 over the past decade. While the company's 10-year median is 150.89 vs. the industry median of 113.36, Concord Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Biotech's current Days Payable of 108.36 is 4.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current Days Payable is 108.36, which is 28% below median its own 10-year median of 150.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,666.31, compared to a current price of ₹1,257.00 — trading 24.6% below its estimated fair value. The current Days Payable is 108.36, which is 28% below median its 10-year median of 150.89 and 4.4% below the Biotechnology industry median of 113.36. Concord Biotech's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current Days Payable is 108.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (BOM:543960) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,257.00 is trading 24.6% below its estimated GF Value™ of ₹1,666.31.
GuruFocus considers Concord Biotech to be Modestly Undervalued.
Key valuation signals for BOM:543960:
Days Payable: 108.36 (28% below median its 10-year median of 150.89)
GF Value™: ₹1,666.31 vs. price of ₹1,257.00 (24.6% below fair value)
Industry Position: 4.4% below the Biotechnology median (#303 of 701)
No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
68GF Score
Get the complete analysis for BOM:543960
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543960 has been successfully added to your 
